Neocitrin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Neocitrin

Property Description
Active Ingredients Bacitracin and Neomycin
Form Topical Ointment and Dusting Powder
Pharmacological Class Antibiotic; Broad-spectrum antibacterial agents
Common Use Prevention of superficial infection in minor wounds
Origin Derived (from bacterial and fungal sources)

Neocitrin is defined as a combination drug classified as a topical antibiotic intended solely for external use on the skin. This product, recognized as a first-aid antibiotic, belongs to the broad-spectrum antibacterial agents pharmacological class, providing localized defense against bacterial proliferation on the skin surface. The medicine's efficacy stems from its two principal active ingredients: Bacitracin and Neomycin.

The Bacitracin component, a cyclic polypeptide antibiotic, is derived from Bacillus species, while Neomycin, an aminoglycoside, is derived from Streptomyces fradiae. This combination targets a wider array of microorganisms, utilizing two distinct mechanism principles to achieve its comprehensive antibacterial effect. The availability of Neocitrin in multiple drug forms—an ointment and a dusting powder—provides users with a choice depending on the nature of the wound.

The primary general purpose of Neocitrin is the reliable prevention of infection following commonplace minor skin injuries. This combination is intended for use as a safe and effective option for its specific purpose. The application of this topical preparation is directed at cuts, scrapes, and burns to deter the growth of bacteria, thereby supporting the body's natural healing process after minor skin trauma.

What side effects are possible with Neocitrin?

Possible Side Effects and Safety Information

The safety profile of topical Bacitracin and Neomycin is defined by potential local reactions and strict constraints on use, as detailed in official regulatory documents.

Adverse Reactions and Systemic Risk

Adverse reactions most often reported in regulatory summaries are localized allergic sensitization reactions. These primarily involve the Skin and Subcutaneous Tissue Disorders and can manifest as localized rash, itching, reddening, or swelling. In some cases, a failure of the wound to heal may be a sign of a developing sensitization.

Though classified as rarely reported, serious adverse reactions are associated with the potential for systemic absorption of the Neomycin component, particularly when applied over large or compromised skin areas. These serious risks include Systemic Ototoxicity (risk of permanent bilateral deafness) and Systemic Nephrotoxicity (risk of kidney damage), which necessitate cautious use.

Category Regulatory Safety Note
Time-Related Pattern Prolonged use increases the risk of sensitization and superinfection (overgrowth of non-susceptible organisms).
Serious Constraint Must not be used over large body areas due to the risk of systemic absorption.

Population-Specific Safety Considerations

The medicine is officially not recommended for use in infants and neonates due to the enhanced risk of systemic absorption through immature skin. Caution is also required in individuals with pre-existing nerve deafness and those with extensive skin damage (such as burns or trophic ulcers), where increased systemic exposure may lead to neurotoxicity. Use is contraindicated in individuals with a known history of hypersensitivity to Bacitracin, Neomycin, or related aminoglycosides.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Neocitrin is defined by the potential for systemic absorption of its active components, Bacitracin and Neomycin, a risk primarily associated with accidental ingestion or application over large areas of broken skin or wounds. The resulting toxicity targets specific physiological systems as documented in regulatory information, requiring focused monitoring and immediate emergency action when necessary.

Documented Overdose Manifestations

System Affected Potential Severe Manifestation
Renal System Nephrotoxicity, potentially leading to signs like azotemia and acute renal failure.
Auditory/Vestibular System Ototoxicity, which may result in irreversible hearing loss or tinnitus.
Neuromuscular System Neuromuscular blockade, a documented risk factor for respiratory paralysis.

Required Emergency Actions

It is officially mandated that for suspected accidental ingestion or the onset of serious reactions—such as difficulty breathing or severe dizziness—users seek immediate medical attention or contact a Poison Control Center right away. Due to the lack of a known specific antidote, management involves symptomatic and supportive treatment. Hospital monitoring of renal and auditory function may be required following an overdose incident, particularly for populations with impaired renal function who face an increased risk of systemic toxicity.

Therapeutic Uses of Neocitrin

Localized Defense Against Minor Wound Contamination

Within its therapeutic context, Neocitrin is classified as a first-aid antibiotic. This medication is commonly used to help with acute management of minor skin trauma, addressing the symptoms related to physical discomfort caused by superficial cuts, scrapes, and small burns. It is applied across domains where additional symptomatic support is needed, such as when the skin barrier is compromised. By creating a localized anti-infective defense against bacterial contamination, the preparation supports the body's natural healing process, which contributes to improved day-to-day comfort during the recovery phase.


Management of Superficial Bacterial Conditions

The medication is relevant for easing symptoms that cluster into patterns requiring supportive management, such as those associated with mild, established, superficial bacterial infections. It is applied in settings marked by temporary physiological imbalance, including certain pyodermas or instances where inflammatory skin conditions develop a secondary bacterial component. The specialized dusting powder formulation is applied in addressing lesions presenting with moisture or oozing, which contributes to easing the overall symptom load associated with these irritative states. The medication is used in conditions presenting with localized discomfort, such as minor cuts, scrapes, and minor burns.

“This supportive therapeutic benefit helps ease the overall symptom burden of the injury.”


Supporting Unhindered Tissue Repair

Neocitrin is utilized in clinical scenarios that require short-term supportive relief and protection following injury, often used in the context of first-aid and home wound care. This supportive therapeutic benefit assists with maintaining functional stability when symptoms are more noticeable.

Quick Fact: Supportive relief for acute skin trauma

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Neocitrin

This section describes the officially documented population eligibility and non-eligibility for the topical antibiotic combination Neocitrin (Bacitracin/Neomycin), as stated in regulatory documents.


Populations for Whom Use is Contraindicated

Individuals with a known hypersensitivity or allergy to Neomycin, Bacitracin, or any other ingredient in the product must not use it. The medicine is prohibited from use in the eyes, and its application for self-treatment of deep cuts, puncture wounds, animal bites, or serious burns is not authorized.


Conditional and Restricted Use

Use of Neocitrin is strictly limited to the external surface of the skin. It is prohibited from application over large areas of the body and should not exceed 7 days unless directed by a healthcare provider. Eligibility is conditional for individuals with pre-existing kidney disease or hearing problems due to the risk of systemic absorption; consultation with a healthcare professional is required.


Age and Reproductive Status

Use in the pediatric population is restricted: consultation with a doctor is necessary for infants and for application to broken skin in the diaper area. For pregnancy, use is conditional, permitted only if clearly needed. Breastfeeding women must use caution and thoroughly wipe off the application area before nursing.

What should I know about interactions with other medicines?

Official Interaction Restrictions and Risks

The official interaction profile for this combination topical antibiotic is defined by constraints related to the potential for systemic absorption of its active components when applied to compromised skin, such as large, broken, or burnt areas. Regulatory documents specify restrictions for co-administration with other medicines that share similar potential for systemic adverse effects.

Documented Interaction Categories

  • Neuromuscular Blocking Agents: Co-administration is restricted due to the Neomycin component's potential to produce neuromuscular blockade, which may intensify and prolong respiratory depressant effects when used with agents like certain anesthetics.

  • Additive Ototoxicity and Nephrotoxicity: Restrictions apply to the concurrent or sequential use of other systemic Aminoglycosides and Potent Diuretics (e.g., Furosemide). These combinations carry a risk of additive toxicity to the ear and kidneys if the topical components are absorbed systemically.

  • Other Nephrotoxic Drugs: Co-administration with agents such as Cisplatin or Vancomycin is restricted, particularly when applied over large surface areas, due to the potential for additive kidney toxicity from the Bacitracin component.

Population and Condition Constraints

The relevance of these systemic interaction warnings is formally noted to be greater in patients with Impaired Renal Function due to the reduced ability to clear the absorbed components. No specific interactions with food, alcohol, or herbal products are officially documented in regulatory labeling.

Mechanism of Action

How Neocitrin Works

Targeting Bacterial Cell Wall Construction

The mechanism begins with Bacitracin, which acts by complexing and sequestering the crucial lipid carrier undecaprenyl pyrophosphate ( C55 -PP), thereby halting the transport of building blocks necessary for the bacterial cell wall assembly. This interruption of cell wall assembly results in the structural collapse and lysis of primarily Gram-positive bacteria.


Inhibiting Bacterial Protein Synthesis

The complementary component, Neomycin, engages a different pathway by binding to the 30S ribosomal subunit, which is the machinery responsible for manufacturing bacterial proteins. This binding causes misreading of the genetic code, resulting in the creation of non-functional, aberrant proteins, which subsequently causes the internal functional disruption of primarily aerobic Gram-negative bacteria.


Mechanistic Complementation and Coverage

The combination utilizes mechanistic complementation by simultaneously addressing two distinct processes—cell wall integrity and protein synthesis. This dual-action approach results in mechanistic coverage against both Gram-positive and Gram-negative bacterial domains.

Dosage and Administration Information

How Neocitrin is Used: General Administration Guidelines

Neocitrin (Bacitracin and Neomycin topical combination) is an external use preparation. The usage pattern defines the appropriate route, frequency, duration, and quantity for application.


Administration Scope

Usage Parameter Instructions
Route of Administration Topical; strictly for external application to the skin only.
Dosing Quantity Apply a small amount of the product onto the affected area of the skin.
Frequency and Duration Apply 1 to 3 times daily, and do not use for more than 7 days in total.
Post-Application Context The treated area may be covered with a sterile bandage.

Procedural Structure and Constraints

The usage protocol establishes the medicine as a short-term, external treatment with a defined application limit. The instruction protocol specifies that the area should be clean and dry before application of the ointment or dusting powder. The product must be administered only on the surface of the skin, and it is advised against its application to large areas of the body. If the condition persists or worsens after the seven-day course, the application should be discontinued.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Neocitrin

Evidence for Prevention of Superficial Wound Infection

The research base explored its use in minor cuts, scrapes, and burns. Most of the evidence available consists of controlled trials, including Randomized Controlled Trials (RCTs), and analyses that compare topical application against an inactive control, such as petrolatum, or against an antiseptic agent. These studies were used in research exploring how clinical infection rates and the presence of bacteria at the wound site change during the recovery period.

Findings from these types of studies describe patterns observed when the two-ingredient combination or similar combinations were used on uncomplicated wounds. When studies included endpoints measuring broad-spectrum activity, this was examined by comparing the two-ingredient formulation to single-ingredient topical antibiotics. Research highlights that results apply only to the populations studied and may not reflect outcomes outside of controlled settings.


Comparison of Outcomes in Controlled Studies

Research examined outcomes related to wound healing and bacterial contamination. Short-term comparative studies explored how the topical combination related to the speed at which the skin re-epithelializes following injury. Researchers monitored endpoints such as the time required for healing in patients with blisters, cuts, or minor surgical wounds.

Studies report how healing evolved in the observed populations. Some studies explored whether application compared to other treatments or controls showed patterns related to healing time. However, the evidence quality varies across these comparisons, and some trials focusing on specific healing endpoints have had modest sample sizes.


Gaps and Uncertainties in the Research Landscape

Much of the available evidence involves studies that used the triple antibiotic formulation (Bacitracin, Neomycin, and Polymyxin B), and its findings are used to contextualize the two-ingredient product. Research provides limited insight into long-term safety and effectiveness patterns, as follow-up durations were limited in most key studies. Certainty remains low regarding the patterns observed in different study groups, and data for specific groups, such as pregnant patients, remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Neocitrin (FAQ)


Q: Is Neocitrin the same as [Common Cold Drug Name]? What's the difference?

The product discussed in this context, Neocitrin, is defined in regulatory documents as a topical antibiotic containing Bacitracin and Neomycin intended for minor skin wounds. However, a product sold under the same brand name may also be a combination oral cold and flu medicine, which contains different active ingredients such as Acetaminophen and Dextromethorphan HBr. The topical and oral products have different components, uses, and routes of administration.


Q: Is Neocitrin a prescription-only medicine?

The topical antibiotic combination containing Bacitracin and Neomycin is generally regulated as an Over-the-Counter (OTC) medicine for its indicated purpose of helping to prevent infection in minor cuts, scrapes, and burns. This classification is noted in regulatory marketing status documents for first-aid topical antibiotics.


Q: Is Neocitrin safe to use long-term?

Regulatory instructions define the maximum recommended duration of use for the topical antibiotic as no more than 7 days in total unless otherwise directed by a healthcare provider. The safety profile notes that prolonged use carries an increased risk of developing an allergic sensitization reaction or a superinfection (an overgrowth of non-susceptible organisms).


Q: Is Neocitrin available in liquid form or chewable tablets?

According to official regulatory labeling, the topical antibiotic combination is officially available in the form of a topical ointment and a dusting powder. Liquid or chewable tablet formulations are not listed for this specific combination used as a first-aid topical antibiotic.


Q: Can older adults use Neocitrin safely?

Official labeling for similar formulations notes that no overall differences in safety or effectiveness have been observed between the elderly population and younger patients. However, official warnings highlight that the risk for serious systemic side effects, such as kidney and hearing issues, is formally noted to be greater in patients with impaired renal function.


Q: Can Neocitrin be used for children of all ages?

Official documents state the medicine is not recommended for use in infants and neonates due to the enhanced risk of systemic absorption through immature skin. Application to broken skin in the diaper area requires consultation with a doctor, as noted in the eligibility constraints. The official topical monograph does not define a lower age limit for general use beyond the infant restriction.


Q: Are there known drug-drug interactions that are specifically dangerous?

Regulatory documents highlight risks when the topical components are absorbed systemically (i.e., if applied to large, compromised areas). Specifically restricted combinations include concurrent or sequential use with Neuromuscular Blocking Agents, other systemic Aminoglycosides (a class of antibiotics), Potent Diuretics, and certain other Nephrotoxic Drugs due to the potential for additive toxicity to the body's systems.


Q: Is it okay to use Neocitrin with over-the-counter pain medication?

Official regulatory documentation for this topical antibiotic primarily focuses on rare, severe interactions that occur if components are absorbed systemically. There are no specific, documented interaction warnings in official labeling regarding the topical use of Neocitrin and the simultaneous use of common oral over-the-counter pain medications.


Q: Does Neocitrin make you feel drowsy or sleepy?

Official safety information regarding the topical antibiotic formulation does not list drowsiness or sleepiness as a common side effect. Potential serious systemic side effects, which are rare and occur with extensive application, include dizziness, which may be related to inner ear toxicity.


Q: What if I miss taking a dose of Neocitrin?

Official guidance describes that if an application is missed, it may be applied as soon as it is remembered. However, if it is almost time for the next scheduled application, the recommendation is to generally skip the missed one and continue the regular schedule. Official guidance also advises not using a double application to compensate for a missed one.


Q: Does Neocitrin affect sleep patterns?

Official regulatory safety documents for the topical antibiotic formulation do not list effects on general sleep patterns as a reported side effect.


Q: Is it safe to drive or operate machinery after taking Neocitrin?

Official warnings regarding driving or operating machinery are generally reserved for medicines that commonly cause central nervous system effects like sedation. No specific regulatory warning exists for the topical antibiotic formulation, though the potential for systemic side effects like dizziness is noted if the product is applied over large or compromised areas.


Q: Does Neocitrin affect blood sugar levels?

Official safety and interaction documents for the topical antibiotic combination do not list effects on blood sugar levels or interactions with common diabetes medications.


Q: What is the difference between Neocitrin and generic versions?

From a regulatory perspective, generic versions of the topical combination contain the same active ingredients (Bacitracin and Neomycin) at the same strength and must meet the same official quality standards as the brand-name product. Differences may exist only in inactive ingredients (excipients).


Q: Does Neocitrin cause changes in mood or anxiety?

Changes in mood or anxiety are not listed in the official adverse reaction summaries for the topical antibiotic formulation. Reported side effects primarily involve localized skin reactions.


Q: Do regulatory bodies recommend any special monitoring while on Neocitrin?

Routine monitoring is not generally recommended for the brief, topical use on minor wounds. However, regulatory warnings highlight that individuals with impaired renal function or those applying the product over large or compromised areas have an enhanced risk of systemic absorption. This noted risk is a factor that may be considered for monitoring by a healthcare provider for potential kidney or hearing issues.


Q: How does the effectiveness of Neocitrin change over time?

Regulatory documents advise against using the product for longer than 7 days. This is because prolonged use carries a risk of developing a superinfection (an overgrowth of non-susceptible organisms). The development of a superinfection is a condition that can complicate wound healing.


Q: Is it normal to feel a little dizzy after taking Neocitrin?

Dizziness is not listed as a common or expected side effect. It is noted in official safety information as a possible symptom related to the rare risk of systemic side effects if the Neomycin component is absorbed into the body when applied over large or severely compromised skin areas.


Q: Does Neocitrin contain any common allergens like gluten or lactose?

The official regulatory labeling for the topical ointment formulation lists the active ingredients and common excipients, such as White Petrolatum. Components like gluten or lactose are typically not included in the formulation of this topical antibiotic, but the complete list of inactive ingredients varies by specific product and can be found on the product label.

How should Neocitrin be stored and disposed of?

Storage and Disposal of Neocitrin

The medicine (combination products containing Acetaminophen, Dextromethorphan HBr, Doxylamine Succinate, and Phenylephrine HCl) must be stored and handled according to official regulatory documentation to maintain stability.

Storage Requirements

The product must be stored at controlled room temperature, typically between 15 C and 30 C (59 F and 86 F). Storage conditions require protection from freezing, excessive heat, light, and moisture.

  • Packaging: Store the product in the outer carton and do not use if the tamper-evident seal or blister is torn or broken.
  • Child Safety: All formulations must be kept strictly out of reach of children.
  • Stability: Do not use the medicine past the expiration date printed on the package.

Disposal Instructions

Safe disposal should prioritize official drug take-back locations. If a take-back option is unavailable, the unused or expired product must be mixed with an undesirable substance (like dirt or coffee grounds) in a sealed container before being placed in household trash. Do not flush the medication down the toilet or pour it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Neocitrin found in:

A-Z Index: